Form 4: Prelude Therapeutics Executive Granted Stock Options

Bryant David Lim, CLO, Interim CFO, and Corporate Secretary of Prelude Therapeutics, was granted stock options for 25,000 shares on May 14, 2024.

Summary

• Bryant David Lim, an officer at Prelude Therapeutics Inc., received stock options on May 14, 2024.
• The options grant was for 25,000 shares of common stock.
• The exercise price of the options is $3.86.
• The options vest over time, starting with 25% vesting on May 14, 2025, and the remainder vesting monthly until fully vested, contingent on continued service.

Sentiment

Score: 6

Explanation: The document is a routine disclosure of stock option grants, which is generally neutral. It indicates that the company is using standard compensation practices.

Positives

• The grant of stock options aligns the executive's interests with those of the shareholders, incentivizing performance and long-term value creation.

Future Outlook

The vesting schedule of the stock options is contingent upon the Reporting Person's continued service to the Issuer.

Industry Context

Stock option grants are a common form of executive compensation in the biotechnology industry, used to attract and retain talent and align their interests with those of shareholders.

Comparison to Industry Standards

• Stock option grants are a standard component of compensation packages for executives in publicly traded biotechnology companies.
• The size and vesting schedule of the grant would need to be compared to similar companies in the pharmaceutical industry to determine if it is in line with industry standards.

Stakeholder Impact

• The stock option grant could potentially dilute existing shareholders if the options are exercised.
• The grant incentivizes the executive to work towards increasing shareholder value.

Key Dates